Genomics and Epigenomics of Gastrointestinal Disorders

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Human Genomics and Genetic Diseases".

Deadline for manuscript submissions: closed (20 June 2023) | Viewed by 7971

Special Issue Editor


E-Mail Website
Guest Editor
Division of Gastroenterology and Hepatology, Department of Medicine, The Penn State University College of Medicine, The Milton S. Hershey Medical Center, Hershey, PA 17033, USA
Interests: functional genomics; microRNA; intestinal inflammation; inflammatory bowel disease; TJ permeability; pancreatic cancer; colorectal cancer

Special Issue Information

Dear Colleagues,

Gastrointestinal disorders such as gastrointestinal cancers and gastrointestinal inflammation are some of the most important health problems globally. Over the last few decades there has been an alarming increase in the overall prevalence of these complications. Despite extensive research efforts, we are still unable to provide precise solutions for the development of novel diagnostic and treatment methods for these problems. In the last decade, genomics and epigenomic advances have presented us with a plethora of knowledge. This has seen a significant increase in our understanding of the various gastrointestinal complications. The goal of this Research Topic is to provide insight into the new discoveries regarding molecular pathways and biomarkers that could improve the diagnosis and/or the prognostic classification of gastrointestinal inflammation and gastrointestinal cancers.

This Research Topic invites the submission of original research and review articles covering the given range of topics. The subject areas we wish to cover include, but are not limited to, the following:

  • Colorectal cancer;
  • Pancreatic cancer;
  • Hepatocellular carcinoma;
  • Gastric cancer;
  • Esophageal cancer;
  • Inflammatory bowel disease (IBD);
  • Intestinal tight junction permeability.

Dr. Manmeet Rawat
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colorectal cancer
  • pancreatic cancer
  • hepatocellular carcinoma
  • gastric cancer
  • esophageal cancer
  • inflammatory bowel disease (IBD)
  • intestinal tight junction permeability

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 7261 KiB  
Article
Coronin 1C, Regulated by Multiple microRNAs, Facilitates Cancer Cell Aggressiveness in Pancreatic Ductal Adenocarcinoma
by Kosuke Fukuda, Naohiko Seki, Ryutaro Yasudome, Reiko Mitsueda, Shunichi Asai, Mayuko Kato, Tetsuya Idichi, Hiroshi Kurahara and Takao Ohtsuka
Genes 2023, 14(5), 995; https://doi.org/10.3390/genes14050995 - 27 Apr 2023
Cited by 1 | Viewed by 1506
Abstract
Coronin proteins are actin-related proteins containing WD repeat domains encoded by seven genes (CORO1A, CORO1B, CORO1C, CORO2A, CORO2B, CORO6, and CORO7) in the human genome. Analysis of large cohort data from The Cancer Genome Atlas [...] Read more.
Coronin proteins are actin-related proteins containing WD repeat domains encoded by seven genes (CORO1A, CORO1B, CORO1C, CORO2A, CORO2B, CORO6, and CORO7) in the human genome. Analysis of large cohort data from The Cancer Genome Atlas revealed that expression of CORO1A, CORO1B, CORO1C, CORO2A, and CORO7 was significantly upregulated in pancreatic ductal adenocarcinoma (PDAC) tissues (p < 0.05). Moreover, high expression of CORO1C and CORO2A significantly predicted the 5 year survival rate of patients with PDAC (p = 0.0071 and p = 0.0389, respectively). In this study, we focused on CORO1C and investigated its functional significance and epigenetic regulation in PDAC cells. Knockdown assays using siRNAs targeting CORO1C were performed in PDAC cells. Aggressive cancer cell phenotypes, especially cancer cell migration and invasion, were inhibited by CORO1C knockdown. The involvement of microRNAs (miRNAs) is a molecular mechanism underlying the aberrant expression of cancer-related genes in cancer cells. Our in silico analysis revealed that five miRNAs (miR-26a-5p, miR-29c-3p, miR-130b-5p, miR-148a-5p, and miR-217) are putative candidate miRNAs regulating CORO1C expression in PDAC cells. Importantly, all five miRNAs exhibited tumor-suppressive functions and four miRNAs except miR-130b-5p negatively regulated CORO1C expression in PDAC cells. CORO1C and its downstream signaling molecules are potential therapeutic targets in PDAC. Full article
(This article belongs to the Special Issue Genomics and Epigenomics of Gastrointestinal Disorders)
Show Figures

Figure 1

Review

Jump to: Research

16 pages, 677 KiB  
Review
The Role of Genetic and Epigenetic Regulation in Intestinal Fibrosis in Inflammatory Bowel Disease: A Descending Process or a Programmed Consequence?
by Sara Jarmakiewicz-Czaja, Aneta Sokal, Katarzyna Ferenc, Elżbieta Motyka, Kacper Helma and Rafał Filip
Genes 2023, 14(6), 1167; https://doi.org/10.3390/genes14061167 - 27 May 2023
Cited by 6 | Viewed by 1384
Abstract
Inflammatory bowel diseases (IBDs) are a group of chronic diseases characterized by recurring periods of exacerbation and remission. Fibrosis of the intestine is one of the most common complications of IBD. Based on current analyses, it is evident that genetic factors and mechanisms, [...] Read more.
Inflammatory bowel diseases (IBDs) are a group of chronic diseases characterized by recurring periods of exacerbation and remission. Fibrosis of the intestine is one of the most common complications of IBD. Based on current analyses, it is evident that genetic factors and mechanisms, as well as epigenetic factors, play a role in the induction and progression of intestinal fibrosis in IBD. Key genetic factors and mechanisms that appear to be significant include NOD2, TGF-β, TLRs, Il23R, and ATG16L1. Deoxyribonucleic acid (DNA) methylation, histone modification, and ribonucleic acid (RNA) interference are the primary epigenetic mechanisms. Genetic and epigenetic mechanisms, which seem to be important in the pathophysiology and progression of IBD, may potentially be used in targeted therapy in the future. Therefore, the aim of this study was to gather and discuss selected mechanisms and genetic factors, as well as epigenetic factors. Full article
(This article belongs to the Special Issue Genomics and Epigenomics of Gastrointestinal Disorders)
Show Figures

Figure 1

23 pages, 439 KiB  
Review
Genetic and Epigenetic Etiology of Inflammatory Bowel Disease: An Update
by Sara Jarmakiewicz-Czaja, Magdalena Zielińska, Aneta Sokal and Rafał Filip
Genes 2022, 13(12), 2388; https://doi.org/10.3390/genes13122388 - 16 Dec 2022
Cited by 13 | Viewed by 4581
Abstract
Inflammatory bowel disease (IBD) is a chronic disease with periods of exacerbation and remission of the disease. The etiology of IBD is not fully understood. Many studies point to the presence of genetic, immunological, environmental, and microbiological factors and the interactions between them [...] Read more.
Inflammatory bowel disease (IBD) is a chronic disease with periods of exacerbation and remission of the disease. The etiology of IBD is not fully understood. Many studies point to the presence of genetic, immunological, environmental, and microbiological factors and the interactions between them in the occurrence of IBD. The review looks at genetic factors in the context of both IBD predisposition and pharmacogenetics. Full article
(This article belongs to the Special Issue Genomics and Epigenomics of Gastrointestinal Disorders)
Back to TopTop